TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

66 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

63 studies on the map

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) — University of Arizona, TucsonMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanEfficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes — Kailera Clinical Site, CullmanMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — MFA Clinical Research, TuscaloosaA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Pinnacle Research Group, AnnistonA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Neighborhood Healthcare, EscondidoEfficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — AMR Clinical, MobileEfficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes — Kailera Clinical Site, GlendaleEfficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes — Kailera Clinical Site, AnnistonA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Birmingham Clinical Research, BirminghamA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight — Cullman Clinical Trials, CullmanA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Lakeview Clinical Research, GuntersvilleA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Birmingham Clinical Research, BirminghamEfficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — Cahaba Research, Inc., PelhamA Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Arizona Research Center, Inc., PhoenixA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain — MD First Research - Chandler, ChandlerA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide — Helios Clinical Research - Phoenix, PhoenixAMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Neighborhood Healthcare, EscondidoAMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — South Broward Research LLC, MiramarAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Dignity Health, Mercy Gilbert, GilbertAMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss — Pinnacle Research Group LLC, AnnistonA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Uni of Alabama at Birmingham, BirminghamA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixAMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Artemis Insitute for Clin Res, San DiegoAMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Univ of Alabama Birmingham, BirminghamMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — Valley Clinical Trials, NorthridgeA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) — Children's Hospital Los Angeles, Los AngelesA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerPhase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy — Central Research Associates, LLC dba Flourish Research, BirminghamMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CitySemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation — The University of Arizona College of Medicine- Phoenix, PhoenixTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoSemaglutide for Post-Smoking Cessation Weight Management — The University of Texas at Austin, AustinComparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes — University Health System Texas Diabetic Institute, San AntonioTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation — Cleveland Clinic, ClevelandFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaEffect of Tirzepatide on Markers of MASLD in Patients With Obesity — University of New Mexico Health Sciences Center, AlbuquerqueTirzepatide in Obesity-Driven Endometrial Cancer — Lineberger Comprehensive Cancer Center, Chapel HillIncretin Microdosing for Cardiometabolic Health in People With HIV — The University of Texas Health Science Center at Houston, HoustonTirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity — Clinical and Translational Research Unit, Palo AltoObesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment — Yale Pediatric Diabetes Center, Adult and Children's Progam, New HavenGlucagon-Like Peptide-1 Receptor Agonist in ADPKD — University of Colorado - Anschutz Medical Campus, AuroraEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity — Massachusetts General Hospital, BostonRole of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome — University of Colorado Anschutz/Children's Hospital Colorado Aurora, AuroraEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder — Johns Hopkins University, BaltimoreTirzepatide for Alcohol Use Disorder — Keck School of Medicine, University of Southern California, Los AngelesBone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy — University of Virginia Medical Center, CharlottesvilleRandomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss — Rush University Medical Center, ChicagoResistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity — St. Jude Children's Research Hospital, MemphisEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioThe Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes — Mayo Clinic in Rochester, RochesterRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontInterleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease — Houston Methodist Research Institute, Houston